Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
about
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Prediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseasesTranslating slow-binding inhibition kinetics into cellular and in vivo effectsDose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.Pharmacokinetics of recombinant bifunctional fusion proteins.Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.Population pharmacokinetics of exenatideThe Øie-Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus.A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug dispositionDynamics of target-mediated drug disposition: characteristic profiles and parameter identification.Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition.Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.Target-mediated drug disposition model and its approximations for antibody-drug conjugates.Theoretical considerations of target-mediated drug disposition models: simplifications and approximations.Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing.Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.
P2860
Q30930928-A6E12049-D22E-4A06-873E-A11DBAF217D7Q33655344-A69F2FA6-0C62-48F3-A404-9B0AA83BCC69Q34204024-C2A36CAD-881E-48B7-AC38-0E9405B45087Q35049579-91C5F89A-1F2F-4196-B3E3-3EA22535001EQ35954896-B76D4E2B-C459-4B0A-A79A-26EB051F0184Q36185667-8601CBAE-0790-4EFE-90E8-8E86AF78E649Q36354544-4AD9BBBB-E2C0-4431-8750-3D97E59E9FDBQ36706795-33AAB7E8-3382-4805-81F5-A7226F36259AQ37030693-9D95EEF3-EBDD-49DE-93E8-6CD25FBB3EF4Q37033032-0DF1D6F8-A579-4BC3-95F9-D8899600E8D6Q37100575-B2F601E2-F9D1-4F9E-8172-9C6B2BEA009CQ37639905-77576A64-373A-4130-B623-797253007D2FQ37932558-B4D13CFC-E0B7-414E-8DCD-4EAEBF3E7B52Q38072598-A17CAF9D-0D26-4892-B389-01AD122A2CF3Q38452569-61F7DF5E-DBC6-4172-B418-A58EE94A0223Q38453769-AD32E66F-C1ED-46EC-966D-55455632EDBAQ38504671-1F64EABF-C0AA-48A2-B913-162E15775A74Q38722944-F37B2BD4-CC6C-4C04-9922-6746DDB1283BQ39130536-2BCA86A5-4FD8-4A9A-87CD-D8AE07D7A923Q40832869-2440042D-4C6C-4B55-A86F-757BB0CF4389Q41915506-7DF61720-C992-4B45-A726-47DD025BEBC1Q41988329-5C5E2B5A-62F4-4622-BEEE-7319CCDF37E5Q41998537-0A3AD7AB-4BB1-4224-A55F-D154935F152BQ42351659-8355E7CA-E3EA-4BC9-8490-E9829519B379Q42424619-2972D5FF-43CD-4D72-92C9-7FF43ED6F0BCQ43635728-D3802A55-92A1-4B49-B7AB-5BE9AE5A21A6Q44384126-A34C36F2-2407-4480-9CDE-B34A16F0FF68Q46045236-B460B089-A79D-45E7-8CAF-6ACEF6733697Q51000653-89263BB1-DCBF-4B87-941B-DE1C2FC12656Q51494132-BBE6E7A5-748B-49DB-AE37-B6B3ABAF06D9
P2860
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Selection between Michaelis-Me ...... sition pharmacokinetic models.
@ast
Selection between Michaelis-Me ...... sition pharmacokinetic models.
@en
type
label
Selection between Michaelis-Me ...... sition pharmacokinetic models.
@ast
Selection between Michaelis-Me ...... sition pharmacokinetic models.
@en
prefLabel
Selection between Michaelis-Me ...... sition pharmacokinetic models.
@ast
Selection between Michaelis-Me ...... sition pharmacokinetic models.
@en
P2093
P2860
P1476
Selection between Michaelis-Me ...... sition pharmacokinetic models.
@en
P2093
Donald E Mager
Wojciech Krzyzanski
Xiaoyu Yan
P2860
P2888
P356
10.1007/S10928-009-9142-8
P577
2009-12-10T00:00:00Z